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Genetic variations in promoter sequences that alter gene expression play a prominent role in increasing susceptibility
to complex diseases. Also, expression levels of APP are essentially regulated by its core promoter and 5′ upstream
regulatory region and correlate with amyloid b levels in Alzheimer disease (AD) brains. Here, we systematically se-
quenced the proximal promoter (5766/+204) and two functional distal regions (52634/52159 and52096/51563)
of APP in two independent AD series with onset ages 70 years (Belgian sample, ; Dutch sample,np 180 np
) and identiﬁed eight novel sequence variants. Three mutations (5118CrA, 5369CrG, and 5534GrA) iden-111
tiﬁed only in patients with AD showed, in vitro, a nearly twofold neuron-speciﬁc increase in APP transcriptional
activity, similar to what is expected from triplication of APP in Down syndrome. These mutations either abolished
(AP-2 and HES-1) or created (Oct1) transcription-factor binding sites involved in the development and differentiation
of neuronal systems. Also, two of these clustered in the 200-bp region (5540/5340) of the APP promoter that
showed the highest degree of species conservation. The present study provides evidence thatAPP-promotermutations
that signiﬁcantly increase APP expression levels are associated with AD.
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The currently most-favored hypothesis advocates a piv-
otal role for the amyloid precursor protein (APP) in
the molecular etiology of Alzheimer disease (AD [MIM
104300]). Clinical mutations in autosomal dominant AD
were shown to increase relative concentrations of the
42-aa amyloid b (Ab) peptide,1–3 a proteolysis product
of APP, which shows increased propensity to aggre-
gate4 and deposit in amyloid plaques in AD brains.5
Also, different missense mutations in the APP gene
(APP [MIM 104760]) cause autosomal dominant early-
onset familial AD6 (Alzheimer Disease & Frontotem-
poral Dementia Mutation Database). Standard molec-
ular diagnostic screening of APP is currently limited to
exons 16 and 17—coding, in part, for the Ab peptide—
and their ﬂanking splice sites. However, it has not yet
been excluded that genetic variation inﬂuencing tran-
scriptional activity of APP also contributes to disease
risk. Ab peptide production depends largely on the
amount of APP substrate; therefore, it is conceivable that
regulation of APP transcription might indeed play an
important role in AD susceptibility. In fact, several stud-
ies have identiﬁed higher levels of APP mRNA in AD
brains (for review, see the work of Theuns and Van
Broeckhoven7), and increased expression of APP has
been correlated with Ab deposition in brain in instances
such as severe head injury.8 Perhaps the most convincing
evidence came from the observation that APP triplica-
tion in patients with Down syndrome (DS) leads to an
overexpression of APP9 and deposition of Ab peptide in
neuritic amyloid plaques,10 which results in a 50-year-
earlier onset of AD symptoms.
APP is expressed in a variety of tissues, with the high-
est expression levels in neuronal cells of the CNS, and
can be induced by a variety of agents, such as growth
hormones and cytokines, as well as stress conditions (for
review, see the work of Theuns and Van Broeckhoven7).
Up-regulation ofAPP transcriptional activity11,12 corrob-
orates the mRNA-expression studies,13,14 which suggests
a major role for the APP promoter activity in APP ex-
pression. The proximal promoter region of APP is de-
void of a functional TATA box and shows a high GC
content, and transcription initiation is regulated by a
strong initiator element (INR) surrounding the major
transcription start site (TSS) 1.15–18 Further, APP pro-
moter activation is mainly governed by two GC-rich ele-
ments, the93/82 fragment (APBb) and the65/41
fragment (APBa).19 Transcriptional activation of APP
can also be mediated by heat-shock factor-1 (HSF-1)
binding to the heat-shock element (HSE) at position
317 after induction by numerous stress factors.20 An-
other transcriptional activator was mapped to 350/
366, which harbors an AP-1 binding site and ﬂanks
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Table 1
Characteristics of Belgian and Dutch Early-Onset AD Study Groups
CHARACTERISTIC
BELGIAN SAMPLE DUTCH SAMPLE
Subjects with AD
( )np 180
Control Subjects
( )np 180
Subjects with AD
( )np 111
Control Subjects
( )np 270
Mean age, in years, at onset/inclusion (SD) 63.8  5.9 59.2  16.7 56.1  5.5 57.5  2.8
Percentage female 55 56 76 60
Percentage of familial ADa 41.5 NA 69 NA
a Familial was deﬁned as the presence of at least one affected ﬁrst-degree relative. NA p not applicable.
Table 2
Mutation Detection Assays
VARIATION(S)
PRIMER
(5′r3′)
PCR Pyrosequencing/Sequencing
Forward Reverse Forward Reverse Pyrosequencing
2335C/T gacgcaatcagcagcataatca ctgggaaggaggaggcaact bio-gatctcggctcacttcaagc aaattagccgggcgtcgt gtagtcccagctac
1901G/T catgcttggtttaacgctctgc gttcactttctgcaccacatttacc attctcctgcctcagcctct bio-gtgaaacccccatctctactaaaaat gctgggattacaggca
1750G/A catgcttggtttaacgctctgc gttcactttctgcaccacatttacc bio-cctgacctcaggtgatctgc gcaaacgtgagaccctttgt attattaagaattttaaggc
534G/A gaaattccaggttgctcgtg bio-ggcgtttctggaagagaatg gggggttaaaaaatgag
479C/T ctgtctcaacaagcaaagaaaatcct bio-gtggggcaggcgtttctg ttaagcttcactcgtt
371G/A and
369C/G cccccgccccgcaaaatc tgggcttcgtgaacagtgggagggagag cccccgccccgcaaaatc tgggcttcgtgaacagtgggagggagag
118C/A atgattcaagctcacggggacgag gctcagagccaggcgagtcagc bio-agggcgctgcacctg ctcggcacccgagaga gaactgcgcccgct
37G/C ggcggcgccgctaggggtctct ctccagcgcccgagccgtccag bio-gggctccgtcagtttcct ccgcgtccttgctctg gggcccccgcgca
NOTE.—Variants 371G/A and 369C/G were detected by sequencing and were conﬁrmed by StuI RFLP. For all other variations, we designed a pyrosequencing
assay.
the GC box.21 Of further interest is the fact that mem-
bers of the NFkb/Rel family can speciﬁcally recognize
two identical sequences at 2250/2241 and 1837/
1822 in the distal promoter region of APP, referred
to as “APPkb sites.”22 Both the expression patterns and
the proximal promoter region of APP are highly con-
served between mammalian species (80%).23–26
Linkage and association studies support the hypothe-
sis that genetic variability at the APP locus might con-
tribute to increased risk for late-onset AD,27–33 in the ab-
sence of coding mutations.34 These genetic data further
suggest that increased susceptibility might result from
genetic mutation in the 5′ regulatory region ofAPP.How-
ever, early on, screenings of the APP promoter in spo-
radic and familial early- and late-onset AD did not reveal
AD-speciﬁc mutations.34–37 More-recent studies detected
a 37G/C polymorphism in APP exon 1 while sequenc-
ing the 573/125 fragment of the APP promoter in
20 individuals.38 The 37 C allele was overrepresented
in patients with late-onset AD who lacked apolipopro-
tein E (APOE) 4 alleles (frequency 17.2%), compared
with elderly control individuals (10%) (odds ratio [OR]
2.08; 95% CI 1.26–3.45; adjusted for age, sex, and edu-
cation). Subsequent sequencing of the 308/124 frag-
ment in 173 patients with late-onset AD and 840 control
individuals revealed one more rare variant in control
individuals, 9G/C (0.7%), that was absent in patients
with AD. However, neither variant, 9G/C or 37G/
C, showed allelic differences in promoter activity when
tested in U-87 glioma cells with use of a reporter gene
assay.
Although these initial results were disappointing, the
existence of AD-related mutations that alter transcrip-
tional activity could not yet be excluded, since only parts
of the APP promoter were analyzed. The APP locus is
known to be complex with several other active sites in
the 5′ regulatory region, apart from the core promoter.
In fact, functional elements that control activity of the
human APP promoter are located in three regions:
2257/2234, 2250/2241, and 1837/1822 (for
review, see the work of Theuns and Van Broeckhoven7).
Therefore, we engaged in a systematic analysis, in two
independent early-onset AD patient and control samples,
of the proximal APP promoter region, as well as two
more-distal regions (2634/2159 and2096/1563)
that were shown to encompass key elements contrib-
uting to high levels of APP expression in different
cell types (for review, see the work of Theuns and Van
Broeckhoven7).
Material and Methods
Patient and Control Groups
Patients with AD ( ) and control individuals (np 180 np
) from the Dutch-speaking Flanders region of Belgiumwere180
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Figure 1 Conservation plot of the APP 5′ upstream region. Plots were generated using the VISTA software, and tracks were presented
on the UCSC Genome Bioinformatics Browser.53 Conserved regions are deﬁned as regions with a conservation score 50% that are 20 bp.
Horizontal black lines crossing the conservation plots mark the 70% conservation boundary. Regions of high conservation are colored as exons
(dark blue), UTRs (light blue), or noncoding sequences (pink).
derived from a prospective study of dementia,39,40 whereas
Dutch patients ( ) and control individuals ( )np 111 np 270
were ascertained in a population-based study of early-onset AD
in the four northern provinces of The Netherlands and in met-
ropolitan Rotterdam. The patients were sampled during two
study periods. The original sample was collected between 1980
and 198741 and was extended between 1997 and 2000 in a
genetically isolated part of the area described above and with
the same sampling criteria.42 Main characteristics of these
study samples are summarized in table 1. Dutch patients re-
ceived a probable diagnosis of AD before age 65 years. Belgian
patients with AD were included if onset age was 70 years;
80 patients had an onset age 65 years. Clinical diagnosis of
probable AD was based on consensus of at least two neurolo-
gists in the Belgian study or of a neurologist and a member
of the research team in the Dutch study, in accordance with
the National Institute of Neurological and Communicative Dis-
orders and Stroke–Alzheimer’s Disease and Related Disorders
Association criteria.43 For all patients, detailed data on family
history of dementia in ﬁrst-, second-, and third-degree relatives
were collected by interviewing a next-of-kin relative of the
patient. The criterion we used for classiﬁcation as familial AD
was the presence of at least one ﬁrst-degree relative with de-
mentia. The criteria for autosomal dominant inheritance were
(1) at least three patients with clinically diagnosed AD in 2
generations and (2) detailed medical records available on the
clinical diagnosis of AD in at least two affected relatives.
On the basis of clinical examination, Belgian and Dutch
control individuals had no neurological or psychiatric antece-
dents and were subjects without organic disease involving the
CNS. Genomic DNA of patients was systematically screened
for mutations in the coding exons of four dementia genes—
PSEN1 (MIM 104311), PSEN2 (MIM 600759),MAPT (MIM
157140), and PRNP (MIM 176640)—and exons 16 and 17
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of APP. We identiﬁed putative causal missense mutations in
eight Belgian patients (4% of the Belgian sample; four muta-
tions in PSEN1, three in PSEN2, and one in APP [N.B., un-
published data]), and in seven Dutch patients (6% of theDutch
sample; ﬁve mutations in PSEN1 and two in PSEN2).42,44 This
study was approved by the medical ethics committee of the
University of Antwerp.
Sequence Analysis of the APP 5′ Regulatory Region
The proximal promoter region of APP (766/204) was
ampliﬁed by PCR with use of three overlapping primer sets
(ﬁg. 1): APP766F (5′-cccccgccccgcaaaatc-3′) and APP218R
(5′-tgggcttcgtgaacagtgggagggagag-3′), APP356F (5′-atgattca-
agctcacggggacgag-3′) and APP25R (5′-gctcagagccaggcgagtc-
agc-3′), and APP99F (5′ggcggcgccgctaggggtctct-3′) and APP
204R (5′-ctccagcgcccgagccgtccag-3′). The distal promoter frag-
ments (2634/2159 and2096/1563) were ampliﬁed using
two additional primer sets: APP2634F (5′-gacgcaatcagcagcat-
aatca-3′) and APP2159R (5′-ctgggaaggaggaggcaact-3′) and
APP2096F (5′-catgcttggtttaacgctctgc-3′) andAPP1563F (5′-
gttcactttctgcaccacatttacc-3′). Oligonucleotide primers for PCR
ampliﬁcation of the APP promoter were based on GenBank
accession number D87675.1. Numbering is relative to the ma-
jor TSS 1 at nt 9001 in D87675.1. About 20 ng genomic
DNA was ampliﬁed in a total reaction volume of 25 ml con-
taining 10 pmol of each primer, 0.2 mM dNTPs (dATP, dCTP,
and dTTP) (Amersham), 0.5 mM 7-deaza-dGTP (Amersham),
0.5 U Platinum or Titanium Taq DNA polymerase (Invitro-
gen), and 1# Platinum/Titanium Taq reaction buffer. Further
reaction conditions were thoroughly optimized for each primer
set (available on request). PCR products were screened for
mutations by direct sequencing with BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems) on the ABI3730
automated DNA sequencer (Applied Biosystems) with use of
the PCR primers. Sequences were analyzed using the NovoSNP
software.45 Each of the variations was conﬁrmed by RFLP or
pyrosequencing (table 2) in the respective carriers. To screen
450 age- and sex-matched healthy control individuals, we used
deaza sequencing to detect the variations located between
766 and 218 and pyrosequencing assays for the remaining
variations (table 2). Because of the high GC content of the
APP promoter, it was necessary to perform a nested PCR with
the pyrosequencing primers on the respective promoter PCR
products.
MatInspector46 was applied to investigate the effect of the
variations on putative transcription-factor binding sites (TFBSs),
with use of a core similarity cutoff value of 0.75 and an op-
timized matrix similarity threshold. Conserved sequences were
detected using the VISTA tools.
Luciferase Reporter Gene Constructs
Genomic fragments of the APP proximal promoter were ob-
tained by PCR ampliﬁcation of DNA of patients or asymptom-
atic mutation carriers with use of the APP-766F and APP204R
primers, as described above, and were cloned into the pCR2.1-
TOPO vector (Invitrogen). The integrity of all inserts was con-
ﬁrmed by sequence analysis with the BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems), with use of vector-
speciﬁc primers. Mutant clones were selected and consequently
recloned into the promoterless pGL3 basic vector (Promega)
upstream of the ﬁreﬂy luciferase gene, by use ofKpnI andXhoI.
Transient Transfection in Cultured Mammalian Cells
Human SH-SY5Y neuroblastoma cells were propagated in
a minimal essential medium with Earle’s salt, 10% fetal bo-
vine serum, 2 mM L-glutamine, 200 IU/ml penicillin, 200 g/
ml streptomycin, and 0.1 mM nonessential amino acids (In-
vitrogen). Human HEK293 embryonic kidney cells were prop-
agated in OptiMem (Invitrogen), with 10% fetal bovine serum,
200 IU/ml penicillin, and 200 g/ml streptomycin. For transient
transfection, SH-SY5Y and HEK293 cells were seeded in 24-
well tissue-culture dishes, at and cells per5 57.5# 10 6# 10
well, respectively, and were allowed to recover for 24 h. Cells
were cotransfected with 32 ng (HEK293) or 80 ng (SH-SY5Y)
of pRL-TK plasmid that contained the herpes simplex virus
thymidine kinase promoter upstream of the Renilla luciferase
gene (Promega) and 800 ng of either one of the APP promoter
constructs or one of the control plasmids, with use of 2.4 ml
Lipofectamine 2000 (Invitrogen). Empty pGL3-basic vector was
used as a negative control, and pGL3-promoter plasmid con-
taining the SV40 early promoter upstream of the ﬁreﬂy lucif-
erase gene (Promega) was used as a positive control.
Luciferase Activity
Transfected cells were cultured for 24–36 h, were washed
with 1 ml PBS (Invitrogen), and were lysed with Passive lysis
buffer (Promega). Fireﬂy luciferase activities (LAF) and Renilla
luciferase activities (LAR) were measured sequentially by use
of a Dual-Luciferase reporter assay system (Promega) and a
Veritas Microplate Luminometer with Dual Reagent Injectors
Luminometer (Promega). To correct for transfection efﬁciency
and DNA uptake, the relative luciferase activity (RLA) was cal-
culated as .RLAp LA /LAF R
Electrophoretic Mobility–Shift Assays (EMSAs)
Nuclear factors were extracted from SH-SY5Y cells with
use of the NucBuster Protein Extraction Kit (Novagen). DIG-
labeled single-stranded oligonucleotides (31 bp) spanning each
variant of APP (534GrA,369CrG, and118CrA) were
designed and HPLC puriﬁed. Blunt-ended double-stranded
probes were obtained by annealing the speciﬁc oligonucleotides
with their respective reverse complements and were checked on
a nondenaturing 15% polyacrylamide gel in 0.25# Tris-bo-
rate-EDTA (TBE). For the binding reactions, a 200-fmol DIG-
labeled double-stranded probe was added to a total reaction
volume of 20 ml containing 10 mg SH-SY5Y nuclear extract,
1# binding buffer (12% glycerol, 20 mM HEPES or TRIS,
50 mM KCl, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF),
and 1 mg poly (dI-dC) (Roche Applied Science). For compe-
tition assays, unlabeled double-stranded probes were added to
the reaction mixture prior to addition of the labeled probe.
Binding reactions were incubated at room temperature for 20
min. Protein-DNA complexes were analyzed by electrophoresis
on nondenaturing 6% polyacrylamide gels in 0.25# TBE and
were visualized by chemiluminescent detection with the DIG
gel-shift kit (Roche Applied Science).
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Table 3
Common Sequence Variants in the APP 5′ Regulatory
Region
Variationa
TFBS Alterationsb
(Core/Matrix Similarity)
2335C/T No matches
1901G/T PAX-6 (.75/.75) and FKHD (.75/.79)
37G/C CDEF (1/.87)
NOTE.—In control individuals, the frequency of var-
iation was 4%.
a Positions relative to the major APP TSS (INR) at nt
9001 in GenBank accession number D87675.1.
b MatInspector analysis.46
Real-Time PCR mRNA Quantiﬁcation
mRNA was isolated from cultured lymphoblast cells of mu-
tation carriers and control individuals by use of the mRNA
Chemagic isolation system (Chemagen), and ﬁrst-strand cDNA
was synthesized from 300 ng of mRNA by use of the Super-
Script III First-Strand Synthesis System for RT-PCR (Invitro-
gen). APP expression levels were quantiﬁed using a Taqman-
MGB real-time PCR assay on the ABI Prism 7900HT Sequence
Detection System (Applied Biosystems). Primers and probes
were designed with the PrimerExpress software (Applied Bio-
systems); sequences are available on request. Human APP
mRNA quantities were normalized for the three housekeeping
genes ubiquitine C (hUBC), b2-microglobulin (hB2M), and tyro-
sine 3-mono-oxygenase/tryptophan 5-mono-oxygenase activa-
tion protein, z polypeptide (hYWHAZ), as recommended by
Vandesompele et al.47 Then, 1/20 fold-diluted cDNA was am-
pliﬁed in a 20-ml reaction containing 1# qPCR Mastermix
Plus (no UNG [Eurogentec]), 300 nM primers, and 250 nM
probe, by use of the universal ampliﬁcation protocol (Applied
Biosystems).
Statistical Analysis
The Mann-Whitney U test, a nonparametric analogue to the
unpaired t test, was used to compare the RLA produced by
the wild-type (WT) and mutant transfectants, as well as real-
time PCR quantiﬁcations of APP expression levels.
Results
Variation in the 5′ Regulatory Region of APP
We sequenced the766/204 region of the proximal
APP promoter (ﬁg. 1) and exon 1 and two more-distal
promoter regions 2634/2159 and 2096/1563, in
two independently ascertained Dutch-speaking groups
with early-onset AD composed of 180 Belgian and 111
Dutch patients (table 1). In total, we identiﬁed nine het-
erozygous sequence variants and conﬁrmed their pres-
ence in the respective carriers by a second method; that
is, PCR-RFLP analysis or pyrosequencing (tables 3–5).46,48
Analysis of 450 age- and sex-matched healthy control
individuals (180 Belgian; 270 Dutch) demonstrated that
three (33%) of the nine variants were known polymor-
phisms: 2335C/T (rs364091),1901G/T (rs1235879),
and 37G/C (rs459543) (table 3); the last is the same
one reported by Athan and colleagues.38 Also in agree-
ment with that study, the 9G/C variant was not ob-
served in the patients with AD. Six (67%) of the nine
variations were present in patients only (table 4). One
Dutch patient, d807, whose age at onset was 50 years,
was a compound heterozygote for two promoter mu-
tations, 1750GrA and 118CrA. One other muta-
tion, 369CrG, was identiﬁed in two familial patients,
d811 (Dutch) and d1081 (Belgian), with very similar
onset ages: 63 and 61 years, respectively. Haplotype
analysis in these patients identiﬁed shared alleles at ﬁve
neighboring microsatellite markers in the 210-kb APP
region, suggestive of a potential common ancestor, al-
though the shared haplotype had a frequency of 1% in
control individuals. Another familial Dutch patient, d786,
carried the534GrAmutation. In two Belgian patients,
d4605 and d5165, with ages at onset of 55 and 62 years,
respectively, the 371GrA and 479CrT mutations
were identiﬁed, respectively. Neither of the patients with
familial AD fulﬁlled our criteria for autosomal dominant
AD.
To investigate to what extent genetic variability in the
APP promoter was patient related, we sequenced the
766/204 proximal promoter region in 48 control in-
dividuals. We identiﬁed only two additional rare poly-
morphisms, 343A/C and 375G/C, that were each
present in one control individual (table 5). Also, since
four of six mutations identiﬁed in patients were located
in the 766/218 region, we sequenced this 548-bp
region in all 450 control individuals but did not detect
any additional variants.
Transcriptional Activity of APP-Promoter Mutations
We cloned the 766/204 APP promoter fragment
that contained WT or mutant 534A, 479T, 371A,
369G, or 118A alleles into the pGL3 basic vector
upstream of a ﬁreﬂy luciferase reporter gene. As con-
trols, we used the 375C and 343C alleles, which
were identiﬁed in control individuals. Reporter gene
assay of transiently transfected human embryonic kid-
ney (HEK293) cells showed no signiﬁcant differences
in expression level between (1)534A,479T,371A,
369G, and 118A and (2) WT promoter sequences.
Also, real-time PCR APP mRNA quantiﬁcation in lym-
phoblasts from the mutation carriers ( ) did notnp 2
reveal signiﬁcant differences in expression levels, com-
pared with control individuals (data not shown). How-
ever, in human neuroblastoma (SH-SY5Y) cells, a sig-
niﬁcant ( ), nearly twofold increase in APP tran-P ! .001
scriptional activity was observed for three of the ﬁve
mutant alleles identiﬁed in patients with early-onset AD:
534A, 369G, and 118A (ﬁg. 2). The other two
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Table 4
Sequence Variants in the APP 5′ Regulatory Region of Patients with Early-Onset AD
Variationa and
Patient ID Nationality
Age at Onset
(years)
Ageb
(years)
Family
History
APOE
Genotypec
TFBS Alterationsd
(Core/Matrix Similarity)
1750GrAe: No major changes
d807 Dutch 50 *64  34
534GrA: OCT1 (.89/.92)
d768 Dutch 52 *70  34
479CrT: GAGA (.750/.789) and OCT1 (.771/.843)
d5165 Belgian 62 *69  33
371GrA: AP2 (.976/.916) and STAF (.904/.799)
d4605 Belgian 55 64  33
369CrG: AP-2 (1/.92)
d811 Dutch 63 *Unknown  34
d1081 Belgian 61 75  44
118CrAe: AP-2 (1/.91) and HES-1 (.83/.92)
d807 Dutch 50 *64  34
a Positions relative to the major APP TSS (INR) at nt 9001 in GenBank accession number D87675.1.
b Current age or age at death (indicated by an asterisk [*]).
c APOE was genotyped as described elsewhere.48
d MatInspector analysis.46
e Patient d807 is compound heterozygous for these mutations.
Table 5
Sequence Variants in the APP 5′
Regulatory Region of Control Individuals
Variationa
Control
ID
TFBS
Alterationsb
(Core/Matrix
Similarity)
375G/C d3155 SP1 (1/.915)
343A/C d3099 No alterations
NOTE.—Both individuals were aged 56
years at the time of inclusion in the study.
Their APOE genotype was 33. APOE was
genotyped as described elsewhere.48
a Positions relative to the major APP TSS
(INR) at nt 9001 inGenBank accession num-
ber D87675.1.
b MatInspector analysis.46
mutant alleles, 479T and371A, did not signiﬁcantly
increase transcriptional activity ( and ,Pp .08 Pp .8
respectively). Neither of the two variant alleles found in
control individuals signiﬁcantly altered transcriptional
activity of the APP promoter in either of the studied cell
types (ﬁg. 2).
Allele-Speciﬁc Transcription-Factor Binding
Using EMSA, we examined whether the three mutant
alleles affecting APP expression (118CrA,369CrG,
and 534GrA) interfered with the speciﬁc recognition
of the APP promoter by nuclear factors extracted from
SH-SY5Y cells. We used 31-bp double-stranded oligo-
mers that contained one of six possible promoter alleles.
We observed that SH-SY5Y nuclear extracts contained
nuclear proteins binding speciﬁcally to all three regions
of the APP promoter, which resulted in the formation
of one or two major complexes (ﬁg. 3). Competition
with 50-fold excess of the respective unlabeled oligomers
resulted in complete inhibition of complex formation.
For 118CrA, one major complex bound to both al-
leles; however, it had a higher binding afﬁnity for the
mutant A allele. The major complex binding to the
369CrG probe showed a decrease in binding afﬁnity
or even a slight shift in complex mobility for the mutant
G allele. Two major complexes were formed on the olig-
omers of the 534GrA variant; however, there were
clear differences in binding afﬁnity for the faster mi-
grating complex, which preferentially bound to the WT
G allele. Also, competition with a 50-fold excess of the
cold534A oligomer did not completely inhibit binding
of the smaller complex to the 534G allele, which sup-
ports the hypothesis of higher binding afﬁnity of this
complex for the G allele.
Discussion
The identiﬁcation of missense mutations in APP led to
the amyloid cascade hypothesis that supports a key role
for increased levels of the more aggregatable Ab42 am-
yloid peptide in the molecular pathogenesis of AD.1,2 The
fact that triplication of APP in patients with DS also
leads to AD pathology suggested that mutations in the
5′ regulatory region increasing APP transcription might
exert a similar effect by increasing the levels of APP
substrate and, by doing so, increase the risk of AD. Al-
though initial studies failed to identify mutations that
affected APP transcription in patients with AD, we iden-
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Figure 2 Transcriptional activity of APP promoter variants. A, Bars represent ﬁreﬂy/Renilla luciferase ratios for the different constructs
(RLA). Values are mean (SEM) of at least eight independent measurements. The signiﬁcance of differences in expression was calculated using
the Mann-Whitney U test. P values are presented above the bars. B, Relative increase of APP promoter activity compared with WT.
tiﬁed six putative mutations in patients with early-onset
AD that were absent from control individuals, by an
extensive analysis of all sequences of the APP 5′ reg-
ulatory region that were shown elsewhere to contain
functional elements. Further, luciferase reporter-gene
analyses of ﬁve proximal APP promoter mutations re-
vealed that three mutations (534GrA,369CrG, and
118CrA) increased APP transcriptional activity sig-
niﬁcantly by nearly twofold in cultured neuroblastoma
cells, compared with two rare variants (375G/C and
343A/C) that we observed in the same promoter seg-
ment in control individuals only. This increased pro-
moter activity correlated with allele-speciﬁc binding of
nuclear factors. The neuron-speciﬁc doubling of expres-
sion is comparable to the increased level of APP expected
from the genomic APP triplication in patients with DS.
Therefore, one could predict that promoter mutations
also cause a critical elevation of APP in vivo in the pa-
tients with AD. We could not expand on this hypothesis,
because we did not have autopsied brain material avail-
able for any of the mutation carriers, since they either
were deceased without autopsy ( ) or are still alivenp 4
( ) (tables 3–5). In line with the absence of an eleva-np 2
tion of APP promoter activity in nonneuronal cells, in-
creased mRNA levels were not observed in lymphoblasts
either. The reliability of our ﬁndings is, moreover, sup-
ported by the fact that all mutation carriers received
a follow-up diagnosis of probable AD. Further, we
observed 100% ( ) correlation in the Belgiannp 55
prospective study and 88% ( ) correlation in thenp 17
Dutch study, with pathological diagnoses for patients
with probable AD (authors’ unpublished data). Also,
quantiﬁcation by ELISA of the abundance of amyloid
b, tau, and phospho-tau in the cerebrospinal ﬂuid of two
Belgian APP mutation carriers showed a decrease of
Ab42 and a slight increase of tau and phospho-tau that
is typical for AD.
The observation that two proximal promoter muta-
tions (479CrT and 371GrA) did not signiﬁcantly
affect APP expression might have two explanations.
These mutations are unrelated to AD and were missed
from our control group because they have a population
frequency !0.11% (!1 of 900 control chromosomes).
Alternatively, the effect of these mutations could not be
observed in vitro because of absence of other necessary
regulatory elements outside the cloned promoter frag-
ment. None of the six proximal promoter variations af-
fected previously proven active TFBSs; however, Mat-
Inspector analysis revealed that all promoter mutations
signiﬁcantly altered one or more TFBS (table 4), with
the exception of distal1750GrA, which was therefore
not analyzed in vitro. The 369G and 118A alleles
abolish a predicted activator-protein-2 (AP-2) binding
site. AP-2 is a cell type–speciﬁc transcription factor crit-
ical for neural gene expression in mammals.49 Several
genes involved in CNS transmitter systems of funda-
mental importance for human behavior have multiple
AP-2 binding sites in their 5′ regulatory regions.50 Ab-
olition of a repressing AP-2 site in the APP promoter
might signiﬁcantly increase its expression. The 118A
allele also abolishes a predicted HES-1 binding site.
HES-1 is a mammalian basic helix-loop-helix (HLH)
transcriptional repressor and a downstream target of the
Notch signaling pathway. Notch signaling and HLH
factors have been demonstrated to regulate numerous
stages of nervous system development, including pro-
liferation of stem and progenitor cells, differentiation
of individual populations of neurons, and maintenance
of mature phenotype and synaptic connectivity of neu-
ronal circuits.51 Neuronal injury induces suppression of
HES-1 expression that may lead to stimulation of neurite
growth and regeneration. The 534A allele creates a
binding site for the octamer binding factor 1 (Oct1), a
member of the POU domain family of transcription fac-
tors. The POU proteins play essential roles in the de-
velopment of highly specialized tissues, such as complex
neuronal systems. More speciﬁcally, the POU domain
was shown to be essential for neurite outgrowth. EMSA
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Figure 3 Allele-speciﬁc binding of transcription factors. EMSA analysis of allele-speciﬁc effect of 118CrA (A), 369CrG (B), and
534GrA (C) on the interaction of nuclear protein complexes extracted from SH-SY5Y cells. DIG-labeled double-stranded probes (200 fmol)
were incubated with 10 mg nuclear extract from SH-SY5Y cells. In competition experiments, 50-fold excess of unlabeled probe was added
before the addition of the labeled probes.
demonstrated that the three promoter mutations that
increased APP expression in vitro showed allele-speciﬁc
binding afﬁnities. It will, however, be necessary to de-
termine whether these particular TFBSs are active ele-
ments that, if altered by the mutation, increase APP ex-
pression. Therefore, it is of interest to mention that Lahiri
et al. reported a correlation between altered TFBS afﬁn-
ities for two known 5′ upstream polymorphisms that alter
APP expression.52 One of these variants (1023T/C), al-
though different from those we described (2335C/T,
1901G/T, and 37G/C), was located in same the 87-
kb linkage disequilibrium (LD) block and was suggested
to be associated with late-onset AD.
Together, our sequencing efforts resulted in a 1.2% (7
of 582) (table 4) allelic frequency of APP proximal pro-
moter variation in patients with early-onset AD, signif-
icantly higher ( ) than the allelic frequency ofPp .037
APP coding mutations—one Belgian patient with early-
onset AD carried the London APP Val717Ile mutation—
of 0.17% (1 of 582) in the same AD groups. Also of
interest is the fact that four mutations were located in
a 200-bp sequence (540 to 340) of the proximal pro-
moter that showed the highest degree of interspecies con-
servation (sequence similarity 195%) of the overall 5′
regulatory region (ﬁg. 1). Moreover, the conservation of
this 200-bp fragment was comparable to the degree of
conservation observed for exon 1. Therefore, replication
studies might focus their attention on this part of the
5′ regulatory region of APP in an attempt to identify
AD-associated mutations. However, ﬁnding new muta-
tions should necessarily be accompanied by reporter-
gene and EMSA analyses, since the two mutations we
identiﬁed in control individuals were also located in this
promoter segment and did not affectAPP transcriptional
activity. Besides the rare mutations, we also identiﬁed
three known polymorphisms, 2335C/T (rs364091),
1901G/T (rs1235879), and37G/C (rs459543) (table
5); the last is the same as that reported by Athan et al.38
The allele frequency of 4% in control individuals was
also similar to that reported for white individuals.38 All
three were in complete LD and were located within the
same 86-kb LD block spanning the APP 5′ upstream
region, from 11 kb upstream of the initiator (rs1235889)
to intron 2 (rs2830053) (International HapMap Pro-
ject). Whereas the study of Athan et al.38 showed a weak
association of 37G/C with late-onset AD, we did not
ﬁnd signiﬁcant association in either the Dutch group
with early-onset AD (OR 0.7; 95% CI 0.2–2.0; Pp
; adjusted for age and sex) or when stratiﬁed forAPOE.5
genotype (OR 1.6; 95% CI 0.2–14.3; ). The ab-Pp .7
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sence of genetic association with the APP promoter in
our Dutch sample with early-onset AD is not surprising,
given the low number of patients carrying mutations in
the APP promoter ( ) (table 4) and since ﬁve of sixnp 6
patients presented with a different mutation.
It has now widely been accepted that genetic causes of
susceptibility to complex diseases reﬂect a different spec-
trum of sequence variants than mutations that dominate
monogenic54–56 disorders. This spectrum includes muta-
tions that alter gene expression; in particular, promoter
mutations have been shown to result in inherited diseases,
including neurodegenerative brain diseases. In Parkinson
disease (PD [MIM 168600]), two mutations were iden-
tiﬁed in the 5′ regulatory region ofNR4A2 (MIM601828)
that cosegregated with familial PD57 and markedly re-
duced NR4A2 mRNA levels. Also, multiple association
studies showed that variations in 5′ regulatory regions of
SNCA (MIM 163890)58,59 and PARK2 (MIM 602544)60
increased PD susceptibility, with some variations increas-
ing disease risk by modulating gene transcription. In AD,
we provided evidence elsewhere that promoter mutations
might explain the increased risk for early-onset AD asso-
ciated with PSEN1 by decreasing expression levels of
PSEN1 in neurons.61,62 Low levels of PSEN1 can lead to
impairment of memory and to synaptic plasticity, fol-
lowed by age-dependent neurodegeneration.63
In conclusion, our study of three functionally active
sequences in the APP 5′ regulatory region with use of
highly sensitive sequencing methods conﬁrmed that the
APP promoter region indeed has a very low genetic var-
iability, with complete absence of common variants.Most
importantly, our study revealed the presence of six AD-
associated mutations, ﬁve of which created or abolished
TFBSs in the APP promoter in six patients with early-
onset AD. Three of these mutations increased APP ex-
pression in vitro in neuroblastoma cells by nearly two-
fold, because of differential TF binding, comparable to
that observed in the case of a genomic triplication of
APP, as in patients with DS. Our data are also in line
with the recent report of APP locus duplication in fam-
ilies with autosomal dominant early-onset AD.64
The frequency of promoter mutations in our popula-
tion was seven times higher than that of coding muta-
tions in exons 16 and 17 of APP. Together, our data
support a role for rare promoter mutations in increasing
risk of early-onset AD. It will, however, be mandatory
to analyze the APP promoter and particularly its 200-
bp conserved proximal promoter fragment, in which
most mutations cluster, in additional independently as-
certained samples of both early- and late-onset AD.
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